메뉴 건너뛰기




Volumn 112, Issue 9, 2008, Pages 1941-1948

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

Author keywords

Androgen deprivation; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

EID: 42449122203     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23388     Document Type: Article
Times cited : (14)

References (19)
  • 1
    • 33846227103 scopus 로고    scopus 로고
    • Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer
    • Maffezzini M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol. 2007;51:605-613.
    • (2007) Eur Urol , vol.51 , pp. 605-613
    • Maffezzini, M.1    Bossi, A.2    Collette, L.3
  • 2
    • 27244451002 scopus 로고    scopus 로고
    • Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    • Zhou P, Chen M-H, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23:6992-6998.
    • (2005) J Clin Oncol , vol.23 , pp. 6992-6998
    • Zhou, P.1    Chen, M.-H.2    McLeod, D.3    Carroll, P.R.4    Moul, J.W.5    D'Amico, A.V.6
  • 3
    • 22844434877 scopus 로고    scopus 로고
    • Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
    • Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294;433-439.
    • (2005) JAMA , vol.294 , pp. 433-439
    • Freedland, S.J.1    Humphreys, E.B.2    Mangold, L.A.3
  • 4
    • 34249940817 scopus 로고    scopus 로고
    • Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
    • Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035-2041.
    • (2007) J Clin Oncol , vol.25 , pp. 2035-2041
    • Stephenson, A.J.1    Scardino, P.T.2    Kattan, M.W.3
  • 5
    • 11144355828 scopus 로고    scopus 로고
    • Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
    • Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
    • (2004) JAMA , vol.291 , pp. 1325-1332
    • Stephenson, A.J.1    Shariat, S.F.2    Zelefsky, M.J.3
  • 6
    • 33947328259 scopus 로고    scopus 로고
    • Prostate-specific antigen in clinical practice
    • Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007;249:30-39.
    • (2007) Cancer Lett , vol.249 , pp. 30-39
    • Loeb, S.1    Catalona, W.J.2
  • 7
    • 3042727071 scopus 로고    scopus 로고
    • Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
    • D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
    • (2004) N Engl J Med , vol.351 , pp. 125-135
    • D'Amico, A.V.1    Chen, M.H.2    Roehl, K.A.3    Catalona, W.J.4
  • 8
    • 27744555727 scopus 로고    scopus 로고
    • Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy
    • Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174:2191-2196.
    • (2005) J Urol , vol.174 , pp. 2191-2196
    • Sengupta, S.1    Myers, R.P.2    Slezak, J.M.3    Bergstralh, E.J.4    Zincke, H.5    Blute, M.L.6
  • 9
    • 22844433445 scopus 로고    scopus 로고
    • Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy
    • D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447.
    • (2005) JAMA , vol.294 , pp. 440-447
    • D'Amico, A.V.1    Renshaw, A.A.2    Sussman, B.3    Chen, M.H.4
  • 10
    • 33947541761 scopus 로고    scopus 로고
    • Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy
    • Palma D, Tyldesley S, Blood P, Liu M, Morris J, Pickles T. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys. 2007;67:1425-1429.
    • (2007) Int J Radiat Oncol Biol Phys , vol.67 , pp. 1425-1429
    • Palma, D.1    Tyldesley, S.2    Blood, P.3    Liu, M.4    Morris, J.5    Pickles, T.6
  • 11
    • 0030843379 scopus 로고
    • Pretreatment prostate specific antigen doubling times; use in patients before radical prostatectomy
    • discussion
    • Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times; use in patients before radical prostatectomy. J Urol. 1997;158:1876-1878; discussion 1878-1879.
    • (1878) J Urol. 1997 , vol.158 , pp. 1876-1878
    • Goluboff, E.T.1    Heitjan, D.F.2    DeVries, G.M.3    Katz, A.E.4    Benson, M.C.5    Olsson, C.A.6
  • 12
    • 0030047278 scopus 로고    scopus 로고
    • Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior
    • Hanks GE, Hanlon AL, Lee WR, Slivjak A, Schultheiss TE. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys. 1996;34:549-553.
    • (1996) Int J Radiat Oncol Biol Phys , vol.34 , pp. 549-553
    • Hanks, G.E.1    Hanlon, A.L.2    Lee, W.R.3    Slivjak, A.4    Schultheiss, T.E.5
  • 14
    • 33745184874 scopus 로고    scopus 로고
    • Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
    • Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
  • 15
    • 21144484803 scopus 로고
    • On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data
    • Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
    • (1993) J Am Stat Assoc , vol.88 , pp. 400-409
    • Gaynor, J.J.1    Feuer, E.J.2    Tan, C.C.3
  • 16
    • 1542532754 scopus 로고    scopus 로고
    • A proportional hazards model for the subdistribution of a competing risk
    • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
    • (1999) J Am Stat Assoc , vol.94 , pp. 496-509
    • Fine, J.P.1    Gray, R.J.2
  • 17
    • 33748672673 scopus 로고    scopus 로고
    • Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level
    • D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006;24:4190-4195.
    • (2006) J Clin Oncol , vol.24 , pp. 4190-4195
    • D'Amico, A.V.1    Loffredo, M.2    Renshaw, A.A.3    Loffredo, B.4    Chen, M.H.5
  • 18
    • 34250795026 scopus 로고    scopus 로고
    • Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors
    • D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007;110:56-61.
    • (2007) Cancer , vol.110 , pp. 56-61
    • D'Amico, A.V.1    Chen, M.H.2    Catalona, W.J.3    Sun, L.4    Roehl, K.A.5    Moul, J.W.6
  • 19
    • 42449109218 scopus 로고    scopus 로고
    • The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: Distant metastasis are the cause
    • Presented at the, Philadelphia, Pennsylvania, November 5-9, Abstract 1132
    • Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: distant metastasis are the cause. Presented at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, Pennsylvania, November 5-9, 2006. Abstract 1132.
    • (2006) 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology
    • Buyyounouski, M.K.1    Hanlon, A.L.2    Horwitz, E.M.3    Pollack, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.